Media coverage about Cellect Biotechnology (NASDAQ:APOP) has been trending somewhat positive this week, according to Accern. Accern rates the sentiment of news coverage by analyzing more than 20 million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Cellect Biotechnology earned a coverage optimism score of 0.05 on Accern’s scale. Accern also gave news coverage about the company an impact score of 46.5257304570853 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the near term.
Several analysts recently commented on APOP shares. HC Wainwright restated a “buy” rating and issued a $14.00 target price (up from $12.00) on shares of Cellect Biotechnology in a research report on Monday, September 25th. ValuEngine cut Cellect Biotechnology from a “hold” rating to a “sell” rating in a research report on Friday, December 1st.
Cellect Biotechnology (NASDAQ APOP) opened at $7.66 on Wednesday. Cellect Biotechnology has a 1 year low of $2.30 and a 1 year high of $13.50.
Cellect Biotechnology Ltd., a biotechnology company, focuses on developing technologies for the functional selection of stem cells in the field of regenerative medicine and stem cell therapies in Israel. It is developing the Apotainer selection kit, a shelf stem cell selection kit, based on its Powered by Cellect technology platform for allogeneic hematopoietic stem cell transplantation procedures for patients suffering from hematological malignancies.
What are top analysts saying about Cellect Biotechnology Ltd.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Cellect Biotechnology Ltd. and related companies.